<p>Inventiva S.A. 赞助的 ADR (NASDAQ:IVA - 获取免费报告) 在三月份经历了大幅减少的空头头寸。截至 3 月 13 日，空头头寸总计为 447,124 股，比 2 月 26 日的 549,755 股减少了 18.7%。根据平均每日交易量 296,385 股，目前的空头头寸比率为 1.5 天。目前，0.5% 的股票被做空。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票研究分析师最近对该公司发布了报告。HC Wainwright 在 1 月 28 日的报告中将 Inventiva 的目标价格设定为 24.00 美元，并给予该股票 “买入” 评级。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Inventiva。他们给予 “买入” 评级，并设定 12.00 美元的目标价格。巴克莱在 1 月 27 日的报告中开始覆盖 Inventiva。他们给予 “增持” 评级，并设定 18.00 美元的目标价格。Truist Financial 在 3 月 19 日的研究报告中开始覆盖 Inventiva。他们对该股票发布了 “买入” 评级，并设定 13.00 美元的目标。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 Inventiva 股票的 “卖出（d-）” 评级。三位研究分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 16.56 美元。</p>
<p><strong>获取我们对 Inventiva 的最新股票分析</strong></p>
<h2>Inventiva 股价下跌 5.2%</h2>
<p>周一中午，IVA 股票下跌 0.30 美元，达到 5.42 美元。该股票交易了 157,501 股，而其平均交易量为 432,078 股。Inventiva 的年低为 2.85 美元，年高为 7.98 美元。该公司的 50 日移动平均价格为 6.30 美元，200 日移动平均价格为 5.38 美元。</p>
<h2>Inventiva 的机构交易</h2>
<p>一些对冲基金和其他机构投资者最近增加或减少了对 IVA 的持股。Creative Planning 在第二季度购买了 Inventiva 的新股份，价值约 32,000 美元。Virtu Financial LLC 在第四季度购买了 Inventiva 的新头寸，价值约 60,000 美元。XTX Topco Ltd 在第四季度购买了 Inventiva 的新股份，价值约 84,000 美元。NewEdge Advisors LLC 在第三季度购买了 Inventiva 的新股份，价值约 116,000 美元。最后，Cerity Partners LLC 在第四季度购买了 Inventiva 的新股份，价值约 93,000 美元。19.06% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Inventiva 公司简介</h2>
<p>(获取免费报告)</p>
<p>Inventiva NASDAQ: IVA 是一家临床阶段的生物制药公司，专注于小分子疗法的发现、开发和商业化，以治疗代谢、炎症和纤维化疾病。该公司的核心专长在于调节核受体和信号通路，这些受体和通路调控纤维化、炎症和代谢功能障碍。Inventiva 的科学平台整合了药物化学、体外和体内药理学以及转化科学，以推进多样化的治疗候选药物管线。</p>
<p>该公司的主要资产 lanifibranor (IVA337) 是一种在开发阶段的全 PPAR 激动剂，针对非酒精性脂肪性肝炎（NASH），并在临床前和临床研究中显示出抗炎和抗纤维化的效果。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Inventiva</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Inventiva 吗？</h2>
<p>在你考虑投资 Inventiva 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Inventiva 并不在名单上。</p>
<p>虽然 Inventiva 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

标普生物技术 3 倍做多 - Direxion

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

纳斯达克生物科技指数 ETF - iShares Nasdaq

2 倍做多纳斯达克生物技术 ETF - ProShares

<p>Inventiva S.A. 赞助的 ADR（纳斯达克代码：IVA）在三月份的空头头寸减少了 18.7%，总计为 447,124 股。目前，0.5% 的股票被做空，基于每日平均交易量 296,385 股，空头头寸比率为 1.5 天。分析师的评级各不相同，其中有三项强烈买入、六项买入和一项卖出。平均目标价格为 16.56 美元。最近，IVA 股票下跌了 5.2%，报 5.42 美元，过去一年价格区间为 2.85 美元至 7.98 美元。机构投资者持有 19.06% 的股份</p>

<p>Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report) was the target of a large decrease in short interest during the month of March. As of March 13th, there was short interest totaling 447,124 shares, a decrease of 18.7% from the February 26th total of 549,755 shares. Based on an average daily volume of 296,385 shares, the short-interest ratio is currently 1.5 days. Currently, 0.5% of the shares of the stock are short sold.</p>
<div class="lb-trans"><p>Inventiva S.A. 赞助的 ADR (NASDAQ:IVA - 获取免费报告) 在三月份经历了大幅减少的空头头寸。截至 3 月 13 日，空头头寸总计为 447,124 股，比 2 月 26 日的 549,755 股减少了 18.7%。根据平均每日交易量 296,385 股，目前的空头头寸比率为 1.5 天。目前，0.5% 的股票被做空。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities research analysts have recently issued reports on the company. HC Wainwright set a $24.00 target price on Inventiva and gave the stock a &#34;buy&#34; rating in a report on Wednesday, January 28th. UBS Group assumed coverage on Inventiva in a research note on Wednesday, January 7th. They set a &#34;buy&#34; rating and a $12.00 price target for the company. Barclays began coverage on Inventiva in a report on Tuesday, January 27th. They set an &#34;overweight&#34; rating and a $18.00 price target for the company. Truist Financial started coverage on Inventiva in a research note on Thursday, March 19th. They issued a &#34;buy&#34; rating and a $13.00 price objective on the stock. Finally, Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Inventiva in a report on Thursday, January 22nd. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of &#34;Buy&#34; and an average price target of $16.56.</p>
<div class="lb-trans"><p>几位股票研究分析师最近对该公司发布了报告。HC Wainwright 在 1 月 28 日的报告中将 Inventiva 的目标价格设定为 24.00 美元，并给予该股票 “买入” 评级。瑞银集团在 1 月 7 日的研究报告中开始覆盖 Inventiva。他们给予 “买入” 评级，并设定 12.00 美元的目标价格。巴克莱在 1 月 27 日的报告中开始覆盖 Inventiva。他们给予 “增持” 评级，并设定 18.00 美元的目标价格。Truist Financial 在 3 月 19 日的研究报告中开始覆盖 Inventiva。他们对该股票发布了 “买入” 评级，并设定 13.00 美元的目标。最后，Weiss Ratings 在 1 月 22 日的报告中重申了对 Inventiva 股票的 “卖出（d-）” 评级。三位研究分析师对该股票给予了强烈买入评级，六位给予了买入评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该股票目前的平均评级为 “买入”，平均目标价格为 16.56 美元。</p>
</div><p><strong>Get Our Latest Stock Analysis on Inventiva</strong></p>
<div class="lb-trans"><p><strong>获取我们对 Inventiva 的最新股票分析</strong></p>
</div><h2>Inventiva Trading Down 5.2%</h2>
<div class="lb-trans"><h2>Inventiva 股价下跌 5.2%</h2>
</div><p>IVA stock traded down $0.30 during mid-day trading on Monday, reaching $5.42. 157,501 shares of the stock traded hands, compared to its average volume of 432,078. Inventiva has a one year low of $2.85 and a one year high of $7.98. The business has a 50-day moving average price of $6.30 and a two-hundred day moving average price of $5.38.</p>
<div class="lb-trans"><p>周一中午，IVA 股票下跌 0.30 美元，达到 5.42 美元。该股票交易了 157,501 股，而其平均交易量为 432,078 股。Inventiva 的年低为 2.85 美元，年高为 7.98 美元。该公司的 50 日移动平均价格为 6.30 美元，200 日移动平均价格为 5.38 美元。</p>
</div><h2>Institutional Trading of Inventiva</h2>
<div class="lb-trans"><h2>Inventiva 的机构交易</h2>
</div><p>A number of hedge funds and other institutional investors have recently added to or reduced their stakes in IVA. Creative Planning bought a new stake in Inventiva in the second quarter worth about $32,000. Virtu Financial LLC bought a new position in shares of Inventiva during the fourth quarter valued at approximately $60,000. XTX Topco Ltd purchased a new stake in shares of Inventiva in the fourth quarter worth approximately $84,000. NewEdge Advisors LLC purchased a new stake in shares of Inventiva in the third quarter worth approximately $116,000. Finally, Cerity Partners LLC bought a new stake in shares of Inventiva during the 4th quarter worth approximately $93,000. 19.06% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>一些对冲基金和其他机构投资者最近增加或减少了对 IVA 的持股。Creative Planning 在第二季度购买了 Inventiva 的新股份，价值约 32,000 美元。Virtu Financial LLC 在第四季度购买了 Inventiva 的新头寸，价值约 60,000 美元。XTX Topco Ltd 在第四季度购买了 Inventiva 的新股份，价值约 84,000 美元。NewEdge Advisors LLC 在第三季度购买了 Inventiva 的新股份，价值约 116,000 美元。最后，Cerity Partners LLC 在第四季度购买了 Inventiva 的新股份，价值约 93,000 美元。19.06% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Inventiva Company Profile</h2>
<div class="lb-trans"><h2>Inventiva 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Inventiva NASDAQ: IVA is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies for the treatment of metabolic, inflammatory, and fibrotic diseases. The company's core expertise lies in the modulation of nuclear receptors and signaling pathways that regulate fibrosis, inflammation and metabolic dysfunction. Inventiva's scientific platform integrates medicinal chemistry, in vitro and in vivo pharmacology, and translational sciences to advance a diversified pipeline of therapeutic candidates.</p>
<div class="lb-trans"><p>Inventiva NASDAQ: IVA 是一家临床阶段的生物制药公司，专注于小分子疗法的发现、开发和商业化，以治疗代谢、炎症和纤维化疾病。该公司的核心专长在于调节核受体和信号通路，这些受体和通路调控纤维化、炎症和代谢功能障碍。Inventiva 的科学平台整合了药物化学、体外和体内药理学以及转化科学，以推进多样化的治疗候选药物管线。</p>
</div><p>The company's lead asset, lanifibranor (IVA337), is a pan-PPAR agonist in Phase III development for nonalcoholic steatohepatitis (NASH) and has demonstrated anti-inflammatory and anti-fibrotic effects in preclinical and clinical studies.</p>
<div class="lb-trans"><p>该公司的主要资产 lanifibranor (IVA337) 是一种在开发阶段的全 PPAR 激动剂，针对非酒精性脂肪性肝炎（NASH），并在临床前和临床研究中显示出抗炎和抗纤维化的效果。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Inventiva</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Inventiva</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Inventiva Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Inventiva 吗？</h2>
</div><p>Before you consider Inventiva, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Inventiva 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已经识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Inventiva 并不在名单上。</p>
</div><p>While Inventiva currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Inventiva 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update

Market Beat

Inventiva SA

Inventiva S.A. 赞助的美国存托凭证 (NASDAQ:IVA) 的空头头寸更新